@article{5307e7a4ffe34472bdd5a6650b9ec72d,
title = "Vitamin B 12 and risk of diabetes: New insight from cross-sectional and longitudinal analyses of the China Stroke Primary Prevention Trial (CSPPT)",
abstract = "Introduction Previous studies in mostly Western populations have yielded conflicting findings on the association of vitamin B 12 with diabetes risk, in part due to differences in study design and population characteristics. This study sought to examine the vitamin B 12 -diabetes association in Chinese adults with hypertension by both cross-sectional and longitudinal analyses. Research design and methods This report included a total of 16 699 participants from the China Stroke Primary Prevention Trial, with pertinent baseline and follow-up data. Diabetes mellitus was defined as either physician-diagnosed diabetes, use of glucose-lowering drugs, or fasting blood glucose (FBG) ≥7.0 mmol/L. New-onset diabetes was defined as any new case of onset diabetes during the follow-up period or FBG ≥7.0 mmol/L at the exit visit. Results At baseline, there were 1872 (11.2%) patients with diabetes; less than 1.5% had clinical vitamin B 12 deficiency (<148.0 pmol/L). Over a median follow-up period of 4.5 years, there were 1589 (10.7%) cases of new-onset diabetes. Cross-sectional analyses showed a positive association between baseline vitamin B 12 levels and FBG levels (β=0.18, 95% CI 0.15 to 0.21) and diabetes (OR=1.16, 95% CI 1.10 to 1.21). However, longitudinal analyses showed no association between baseline vitamin B 12 and new-onset diabetes or changes in FBG levels. Among a subset of the sample (n=4366) with both baseline and exit vitamin B 12 measurements, we found a positive association between an increase in vitamin B 12 and an increase in FBG. Conclusions In this large Chinese population of patients with hypertension mostly sufficient with vitamin B 12, parallel cross-sectional and longitudinal analyses provided new insight into the conflicting findings of previous studies, and these results underscore the need for future studies to consider both baseline vitamin B 12 and its longitudinal trajectory in order to better elucidate the role of vitamin B 12 in the development of diabetes. Such findings would have important clinical and public health implications.",
keywords = "diabetes mellitus, hypertension, longitudinal studies, type 2, vitamin B12",
author = "Lishun Liu and Xiao Huang and Binyan Wang and Yun Song and Tengfei Lin and Ziyi Zhou and Zhuo Wang and Yaping Wei and Huiyuan Guo and Ping Chen and Yan Yang and Wenhua Ling and Youbao Li and Xianhui Qin and Genfu Tang and Chengzhang Liu and Jianping Li and Yan Zhang and Zalloua, {Pierre A.} and Xiaobin Wang and Yong Huo and Hao Zhang and Xiping Xu",
note = "Funding Information: Competing interests XX reports grants from the National Key Research and Development Program (2016YFE0205400, 2018ZX09739010, 2018ZX09301034003), the Science and Technology Planning Project of Guangzhou, China (201707020010), the Science, Technology and Innovation Committee of Shenzhen (JSGG20170412155639040, GJHS20170314114526143, JSGG20180703155802047), and the Economic, Trade and Information Commission of Shenzhen Municipality (20170505161556110, 20170505160926390). YL reports grants from the President Foundation of Nanfang Hospital, Southern Medical University (2017C007, 2018Z009). XQ reports grants from the National Natural Science Foundation of China (81730019, 81973133) and Outstanding Youths Development Scheme of Nanfang Hospital, Southern Medical University (2017J009). HG reports grants from the 111 Project from the Education Ministry of China (B18053). XH reports grants from the National Natural Science Foundation of China (81960074, 81500233), Jiangxi Outstanding Person Foundation (20192BCBL23024), and major projects of the Science and Technology Department, Jiangxi (20171BAB205008). Funding Information: The China Stroke Primary Prevention Trial (CSPPT) was jointly supported by Shenzhen AUSA Pharmed (Shenzhen, China) and national, provincial and private funding, including from the Major State Basic Research Development Program of China (973 Program; grant no. 2102 CB517703); the National Science and Technology Major Projects Specialized for ?? Innovation and Development of Major New Drugs??? during the 12th Five-year Plan Period: the China Stroke Primary Prevention Trial (grant no. zx09101105); a Clinical Center grant (no. zx09401013); the Projects of the National Natural Science Foundation of China (grant no. 81473052, 81441091, and 81402735); the National Clinical Research Center for Kidney Disease, Nanfang Hospital, Nanfang Medical University, Guangzhou, China; the State Key Laboratory for Organ Failure Research, Nanfang Hospital; and research grants from the Department of Development and Reform, Shenzhen Municipal Government (grant no. SFG 20201744). Funding Information: Funding The China Stroke Primary Prevention Trial (CSPPT) was jointly supported by Shenzhen AUSA Pharmed (Shenzhen, China) and national, provincial and private funding, including from the Major State Basic Research Development Program of China (973 Program; grant no. 2102 CB517703); the National Science and Technology Major Projects Specialized for {\textquoteleft}Innovation and Development of Major New Drugs{\textquoteright} during the 12th Five-year Plan Period: the China Stroke Primary Prevention Trial (grant no. zx09101105); a Clinical Center grant (no. zx09401013); the Projects of the National Natural Science Foundation of China (grant no. 81473052, 81441091, and 81402735); the National Clinical Research Center for Kidney Disease, Nanfang Hospital, Nanfang Medical University, Guangzhou, China; the State Key Laboratory for Organ Failure Research, Nanfang Hospital; and research grants from the Department of Development and Reform, Shenzhen Municipal Government (grant no. SFG 20201744). Publisher Copyright: {\textcopyright} 2020 Author(s) (or their employer(s)). Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.",
year = "2020",
month = oct,
day = "6",
doi = "10.1136/bmjdrc-2020-001423",
language = "British English",
volume = "8",
journal = "BMJ Open Diabetes Research and Care",
issn = "2052-4897",
publisher = "BMJ Publishing Group",
number = "1",
}